Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer

NCT00477529 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00477529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00477529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer
Lead sponsor
Celgene
Phase
Phase 1/2
Overall status
Completed
Start date
April 1, 2007
Completion date
June 2, 2011
Enrollment
102 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hormone refractory prostate cancer